Allergy Therapeutics (LON:AGY) Stock Price Down 10.2% – Time to Sell?

Allergy Therapeutics plc (LON:AGY)’s stock price traded down 10.2% on Thursday . The company traded as low as GBX 10.87 and last traded at GBX 10.87. 254,658 shares traded hands during mid-day trading, a decline of 2% from the average session volume of 259,632 shares. The stock had previously closed at GBX 12.10.

Allergy Therapeutics Trading Down 0.8%

The company has a debt-to-equity ratio of 835.48, a quick ratio of 1.48 and a current ratio of 1.63. The company has a market capitalization of £736.97 million, a P/E ratio of -14.29, a PEG ratio of -30.70 and a beta of 1.40. The company’s fifty day simple moving average is GBX 10.35 and its 200-day simple moving average is GBX 8.96.

Allergy Therapeutics Company Profile

Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development.